/
Oncology
Metastatic Melanoma
44
Pipeline Programs↗
42
Active Trials↗
53
Companies Involved↗
Metastatic Melanoma is a moderately active landscape with 44 programs across 53 companies. The most active players are Novartis, Zhuhai Yufan Biotechnologies Co., Ltd, Iovance Biotherapeutics, Inc.. 11 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical9
Phase 17
Phase 217
Phase 311
Approved
No programs
Analysis
Modality Breakdown
68%
Small molecule
25 of 37 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 44 pipeline programs.
Analysis
Trial Status
427
clinical trials
Completed234 · 55%
Terminated83 · 19%
Unknown status39 · 9%
Withdrawn25 · 6%
Recruiting20 · 5%
Active, not recruiting18 · 4%
Other8 · 2%
Clinical Trials
Trial Activity
427 trials
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
Recruiting·—·N/A·NCT07223411·20 enrolled
T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Recruiting·—·Phase 1·NCT06783270·10 enrolled
Page 1 of 29
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)